Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cell Stress Chaperones ; 26(3): 515-525, 2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-33629254

RESUMO

Hyperinflammation distinguishes COVID-19 patients who develop a slight disease or none, from those progressing to severe and critical conditions. CIGB-258 is a therapeutic option for the latter group of patients. This drug is an altered peptide ligand (APL) derived from the cellular stress protein 60 (HSP60). In preclinical models, this peptide developed anti-inflammatory effects and increased regulatory T cell (Treg) activity. Results from a phase I clinical trial with rheumatoid arthritis (RA) patients indicated that CIGB-258 was safe and reduced inflammation. The aim of this study was to examine specific biomarkers associated with hyperinflammation, some cytokines linked to the cytokine storm granzyme B and perforin in a cohort of COVID-19 patients treated with this peptide. All critically ill patients were under invasive mechanical ventilation and received the intravenous administration of 1 or 2 mg of CIGB-258 every 12 h. Seriously ill patients were treated with oxygen therapy receiving 1 mg of CIGB-258 every 12 h and all patients recovered from their severe condition. Biomarker levels associated with hyperinflammation, such as interleukin (IL)-6, IL-10, tumor necrosis factor (TNF-α), granzyme B, and perforin, significantly decreased during treatment. Furthermore, we studied the ability of CIGB-258 to induce Tregs in COVID-19 patients and found that Tregs were induced in all patients studied. Altogether, these results support the therapeutic potential of CIGB-258 for diseases associated with hyperinflammation. Clinical trial registry: RPCEC00000313.


Assuntos
Anti-Inflamatórios/uso terapêutico , Tratamento Farmacológico da COVID-19 , Chaperonina 60/uso terapêutico , Síndrome da Liberação de Citocina/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Anti-Inflamatórios/química , COVID-19/sangue , COVID-19/complicações , Chaperonina 60/química , Síndrome da Liberação de Citocina/sangue , Síndrome da Liberação de Citocina/complicações , Feminino , Humanos , Inflamação/sangue , Inflamação/complicações , Inflamação/tratamento farmacológico , Interleucina-10/sangue , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , SARS-CoV-2/efeitos dos fármacos , Linfócitos T Reguladores/efeitos dos fármacos , Fator de Necrose Tumoral alfa/sangue , Adulto Jovem
2.
Hum Vaccin ; 4(1): 54-9, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18441530

RESUMO

The combined HB-Hib vaccine candidate Hebervac HB-Hib (CIGB, La Habana), comprising recombinant HBsAg and tetanus toxoid conjugate synthetic PRP antigens has shown to be highly immunogenic in animal models. A phase I open, controlled, randomized clinical trial was carried out to assess the safety and immunogenicity profile of this bivalent vaccine in 25 healthy adults who were positive for antibody to HBsAg (anti-HBs). The trial was performed according to Good Clinical Practices and Guidelines. Volunteers were randomly allocated to receive the combined vaccine or simultaneous administration of HB vaccine Heberbiovac-HB and Hib vaccine QuimiHib (CIGB, La Habana). All individuals were intramuscularly immunized with a unique dose of 10 microg HBsAg plus 10 microg conjugated synthetic PRP. Adverse events were actively recorded after vaccine administration. Total anti-HBs and IgG anti-PRP antibody titers were evaluated using commercial ELISA kits at baseline and 30 days post-vaccination. The combined vaccine candidate was safe and well tolerated. The most common adverse reactions were local pain, febricula, fever and local erythema. These reactions were all mild in intensity and resolved without medical treatment. Adverse events were mostly reported during the first 6-72 hours post-vaccination. There were no serious adverse events during the study. No severe or unexpected events were either recorded during the trial. The combined vaccine elicited an anti-HBs and anti-PRP booster response in 100% of subjects at day 30 of the immunization schedule. Anti-HBs and anti-PRP antibody levels had at least a two-fold increase compared to baseline sera. Even more, anti-HBs antibody titer showed a four-fold increase in 100% of volunteers in the study group. The results indicate that the combined HB-Hib vaccine produces increased antibody levels in healthy adults who have previously been exposed to these two antigens. To our knowledge, this is the first demonstration of safety and immunogenicity for a combined vaccine comprising recombinant HBV and synthetic Hib antigens. The present results support phase I-II clinical trial in the target population, two months old healthy infants.


Assuntos
Cápsulas Bacterianas/imunologia , Vacinas Anti-Haemophilus/imunologia , Vacinas contra Hepatite B/imunologia , Vacinas Combinadas/efeitos adversos , Vacinas Combinadas/imunologia , Adulto , Anticorpos Antibacterianos/sangue , Cápsulas Bacterianas/administração & dosagem , Vacinas Anti-Haemophilus/administração & dosagem , Haemophilus influenzae tipo b/imunologia , Anticorpos Anti-Hepatite B/sangue , Anticorpos Anti-Hepatite B/imunologia , Vacinas contra Hepatite B/administração & dosagem , Vacinas contra Hepatite B/efeitos adversos , Vírus da Hepatite B/genética , Vírus da Hepatite B/imunologia , Humanos , Segurança , Vacinas Combinadas/administração & dosagem , Vacinas Sintéticas/administração & dosagem , Vacinas Sintéticas/efeitos adversos
3.
Biotechnol Appl Biochem ; 29(2): 113-7, 1999 04.
Artigo em Inglês | MEDLINE | ID: mdl-10080843

RESUMO

We have previously isolated, cloned and expressed in Escherichia coli the lpdA gene coding for a high-molecular-mass protein (P64k) common to many meningococcal strains. P64k is an outer membrane lipoamide dehydrogenase that is highly immunogenic in animals. Here we describe a preformulation study of the recombinant protein as a vaccine candidate against Neisseria meningitidis, in which six variants containing the candidate were tested. Three assays were used to identify the most suitable variant for further evaluation: percentage of adsorption, identification of P64k by SDS/PAGE, and immunogenicity in mice. All the preformulation variants studied showed more than 98% of adsorption of P64k on the aluminium gel. After desorption, P64k was also identified by SDS/PAGE in the six preformulation variants. Seroconversion was attained in all groups analysed. On the basis of these results, the most effective variant consisted of 20 microg/ml P64k plus 0.5 mg/ml aluminium hydroxide.


Assuntos
Proteínas da Membrana Bacteriana Externa/imunologia , Vacinas Bacterianas/imunologia , Neisseria meningitidis/imunologia , Adjuvantes Imunológicos/química , Adsorção , Hidróxido de Alumínio/química , Animais , Anticorpos Antibacterianos/imunologia , Especificidade de Anticorpos , Ensaio de Imunoadsorção Enzimática , Feminino , Camundongos , Camundongos Endogâmicos BALB C
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...